Compare IHD & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | STIM |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 105.5M |
| IPO Year | N/A | 2018 |
| Metric | IHD | STIM |
|---|---|---|
| Price | $6.46 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 27.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $129,873,000.00 |
| Revenue This Year | N/A | $101.67 |
| Revenue Next Year | N/A | $10.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 78.61 |
| 52 Week Low | $4.49 | $1.25 |
| 52 Week High | $5.47 | $5.92 |
| Indicator | IHD | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 62.95 | 42.76 |
| Support Level | $6.26 | $1.26 |
| Resistance Level | $6.38 | $1.50 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 91.39 | 26.42 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.